← All trials
NCT05432713
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 14, 2022
- Primary completion
- Nov 2, 2022
- Completion date
- Nov 2, 2022
- First posted
- Jun 27, 2022
- Last posted
- Oct 3, 2022
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Lupeng Pharmaceutical Company LTD.Lead sponsor
- Zhejiang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.